What is the share price of Anlon Healthcare Ltd (AHCL) today?
The share price of AHCL as on 16th March 2026 is ₹115.77. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Anlon Healthcare Ltd (AHCL) share?
The past returns of Anlon Healthcare Ltd (AHCL) share are- Past 1 week: 0.77%
- Past 1 month: -5.41%
- Past 3 months: -16.99%
- Past 6 months: 5.99%
- Past 1 year: 26.21%
- Past 3 years: N/A%
- Past 5 years: 26.21%
What are the peers or stocks similar to Anlon Healthcare Ltd (AHCL)?
The peers or stocks similar to Anlon Healthcare Ltd (AHCL) include:What is the market cap of Anlon Healthcare Ltd (AHCL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Anlon Healthcare Ltd (AHCL) is ₹615.33 Cr as of 16th March 2026.What is the 52 week high and low of Anlon Healthcare Ltd (AHCL) share?
The 52-week high of Anlon Healthcare Ltd (AHCL) is ₹172.75 and the 52-week low is ₹90.78.What is the PE and PB ratio of Anlon Healthcare Ltd (AHCL) stock?
The P/E (price-to-earnings) ratio of Anlon Healthcare Ltd (AHCL) is 30.00. The P/B (price-to-book) ratio is 7.65.Which sector does Anlon Healthcare Ltd (AHCL) belong to?
Anlon Healthcare Ltd (AHCL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Anlon Healthcare Ltd (AHCL) shares?
You can directly buy Anlon Healthcare Ltd (AHCL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Anlon Healthcare Ltd
AHCL Share Price
NSE₹115.770.47% (-0.55)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AHCL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AHCL Performance & Key Metrics
AHCL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.75 | 7.65 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.63 | 5.62 | 0.60% |
AHCL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
AHCL Company Profile
Anlon Healthcare Ltd manufactures high purity advanced pharmaceutical intermediates and active pharmaceutical ingredients used in pharmaceutical formulations, nutraceuticals, personal care, and animal health products.
SUNPHARMA
PE Ratio
39.15
39.15
1Y Return
4.63%
4.63%
Buy Reco %
94.12
94.12
TORNTPHARM
PE Ratio
75.55
75.55
1Y Return
39.14%
39.14%
Buy Reco %
81.48
81.48
DRREDDY
PE Ratio
18.80
18.80
1Y Return
10.97%
10.97%
Buy Reco %
51.61
51.61
CIPLA
PE Ratio
19.92
19.92
1Y Return
12.90%
12.90%
Buy Reco %
54.84
54.84
LUPIN
PE Ratio
31.90
31.90
1Y Return
14.99%
14.99%
Buy Reco %
72.22
72.22
AHCL Sentiment Analysis
AHCL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AHCL Stock Summary · February 2026
In Q3 FY26, the company demonstrated robust financial performance, with a significant increase in total income driven by strong demand for Active Pharmaceutical Ingredients (API) and a successful turnaround in Profit After Tax. This growth is supported by an aggressive inorganic strategy, including acquisitions aimed at enhancing capacity and regulatory readiness, while operational efficiency remains a priority with current utilization rates indicating room for expansion. The company is also focused on diversifying its product portfolio and reducing working capital days, which will bolster cash flow management. As it prepares for future growth, the integration of new technologies and strategic acquisitions positions the company favorably in the competitive healthcare market, despite challenges related to capacity constraints and revenue concentration.
AHCL Stock Growth Drivers
AHCL Stock Growth Drivers
6Strong Financial Performance
Anlon Healthcare Limited has reported significant financial improvements, including a total income of ₹35.78 crore
Operational Scaling and Capacity Expansion
The company has made significant strides in operational scaling, with a focus on increasing its
AHCL Stock Challenges
AHCL Stock Challenges
5Operational Performance and Utilization Challenges
The company is currently facing challenges with operational performance, as indicated by the utilization rates
Working Capital Concerns
There are notable concerns regarding working capital management, particularly with the company's receivable days. Currently
AHCL Forecast
AHCL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
AHCL
AHCL
Income
Balance Sheet
Cash Flow
Quarterly Normal View
AHCL Income Statement
AHCL Income Statement
Quarterly Normal View
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 37.89 | 24.21 | 9.38 | 48.97 | 33.31 | 52.23 | 35.78 | |||||||
Operating & Other expenses | 30.98 | 16.64 | 8.78 | 31.74 | 27.06 | 38.46 | 23.24 | |||||||
EBITDA | 6.91 | 7.57 | 0.60 | 17.23 | 6.25 | 13.77 | 12.54 | |||||||
| Depreciation/Amortization | 0.47 | 0.47 | 0.00 | 0.83 | 0.43 | 0.45 | 0.35 | |||||||
| PBIT | 6.44 | 7.10 | 0.60 | 16.40 | 5.82 | 13.32 | 12.19 | |||||||
| Interest & Other Items | 0.98 | 0.93 | 0.89 | 0.91 | 0.82 | 0.87 | 1.58 | |||||||
| PBT | 5.46 | 6.17 | -0.29 | 15.49 | 5.00 | 12.45 | 10.61 | |||||||
| Taxes & Other Items | 0.92 | 3.57 | 2.20 | -1.16 | 1.46 | 3.13 | 5.46 | |||||||
| Net Income | 4.54 | 2.60 | -2.49 | 16.65 | 3.54 | 9.32 | 5.15 | |||||||
| EPS | 2.83 | 0.41 | -0.83 | 4.18 | 0.89 | 2.22 | 1.13 |
AHCL Company Updates
FY 2026FY 2026
Investor Presentation
Feb 19PDF
Nov 19PDF
AHCL Stock Peers
AHCL Past Performance & Peer Comparison
AHCL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Anlon Healthcare Ltd | 30.00 | 7.65 | — |
| Sun Pharmaceutical Industries Ltd | 39.15 | 5.90 | 0.90% |
| Torrent Pharmaceuticals Ltd | 75.55 | 19.02 | 0.75% |
| Dr Reddys Laboratories Ltd | 18.80 | 3.13 | 0.63% |
AHCL Stock Price Comparison
Compare AHCL with any stock or ETFCompare AHCL with any stock or ETF
AHCL
AHCL Holdings
AHCL Shareholdings
AHCL Promoter Holdings Trend
AHCL Promoter Holdings Trend
AHCL Institutional Holdings Trend
AHCL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AHCL Shareholding Pattern
AHCL Shareholding Pattern
AHCL Shareholding History
AHCL Shareholding History
Foreign Institutions
smallcases containing AHCL stock
smallcases containing AHCL stock
Looks like this stock is not in any smallcase yet.
AHCL Events
AHCL Events
AHCL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AHCL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AHCL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
AHCL has not given any dividends in last 5 years
AHCL Dividends
AHCL Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAHCL Stock News & Opinions
AHCL Stock News & Opinions
Articles & Videos
Corporate
Anlon Healthcare to convene board meeting
Anlon Healthcare will hold a meeting of the Board of Directors of the Company on 6 March 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Anlon Healthcare reports standalone net profit of Rs 5.15 crore in the December 2025 quarter
Net profit of Anlon Healthcare reported to Rs 5.15 crore in the quarter ended December 2025 as against net loss of Rs 2.49 crore during the previous quarter ended December 2024. Sales rose 280.13% to Rs 35.58 crore in the quarter ended December 2025 as against Rs 9.36 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales35.589.36 280 OPM %34.686.20 - PBDT10.96-0.29 LP PBT10.61-0.29 LP NP5.15-2.49 LP Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Anlon Healthcare to announce Quarterly Result
Anlon Healthcare will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Anlon Healthcare standalone net profit rises 259.85% in the September 2025 quarter
Net profit of Anlon Healthcare rose 259.85% to Rs 9.32 crore in the quarter ended September 2025 as against Rs 2.59 crore during the previous quarter ended September 2024. Sales rose 115.97% to Rs 52.20 crore in the quarter ended September 2025 as against Rs 24.17 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales52.2024.17 116 OPM %26.3231.07 - PBDT12.906.63 95 PBT12.456.16 102 NP9.322.59 260 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Anlon Healthcare to table results
Anlon Healthcare will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Anlon Healthcare to conduct board meeting
Anlon Healthcare will hold a meeting of the Board of Directors of the Company on 16 October 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Anlon Healthcare to conduct board meeting
Anlon Healthcare will hold a meeting of the Board of Directors of the Company on 27 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Anlon Healthcare is flat on debut
The scrip was listed at 91, matching the initial public offer (IPO) price. So far, the stock has hit a high of Rs 92 and a low of Rs 90.10. On the BSE, over 1 lakh shares of the company were traded in the counter so far. The initial public offer of Anlon Healthcare was subscribed 7.13 times. The issue opened for bidding on 26 August 2025 and it closed on 29 August 2025. The price band of the IPO was fixed between Rs 86 and 91 per share. The IPO comprised a complete fresh issue of equity shares, aggregating up to Rs 121.03 crore. The objectives of the fresh issue include Rs 30.72 crore for funding capital expenditure towards the proposed expansion, Rs 5 crore for repayment/prepayment of certain outstanding borrowings, Rs 43.15 crore for meeting working capital requirements, and the remaining amount for general corporate purposes. The promoters are Punitkumar R. Rasadia, Meet Atulkumar Vachhani and Mamata Punitkumar Rasadia. The promoters and promoter group hold an aggregate of 2,80,00,000 equity shares, aggregating to 70.26% of the pre-offer issued and paid-up equity share capital. Anlon Healthcare is a chemical manufacturing company engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs). Pharma intermediates serve as raw materials or key starting materials for manufacturing APIs. While APIs are used as raw materials in pharmaceutical formulations to produce various types of finished dosage forms, such as tablets, capsules, ointments, and syrups. Besides pharmaceutical applications, these ingredients are also used in nutraceutical formulations, personal care products, and animal health products. As of 20 Aug 2025, the product portfolio consists of 65 commercialized products, 28 products in the pilot stage, and 49 products at the laboratory testing stage/laboratory scale stage. In FY25, APIs accounted for 40.27% of revenue, finished dosage formulations contributed 53.12%, nutraceuticals made up 6.61%, and other segments comprised 0.01%. The firm reported a consolidated net profit of Rs 20.52 crore and total income of Rs 120.29 crore for the twelve months ended on 31 March 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant